Sonnet BioTherapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Segments of Business (Tables)

Segments of Business (Tables)

12 Months Ended

Dec. 31, 2014

Summary of Revenues, Operating Loss, Long-Lived Assets By Geographic Area

The following are revenues, operating loss, and long-lived assets by geographic area as of and for the years ended December 31, 2104 and 2013.

	December 31,
	2014			2013
Revenue:
United States	$	12,941,648		$	987,285
South Africa		6,632,024			5,738,974
Australia		5,613,381			-
Europe		4,656,381			1,521,228
	$	29,843,434		$	8,247,487

Operating Loss:
United States	$	(4,886,279	)	$	(3,931,276	)
South Africa		(373,558	)		(386,168	)
Australia		(277,557	)		-
Europe		(6,914	)		(288,911	)
	$	(5,544,308	)	$	(4,606,355	)

Long Lived Assets:
United States	$	15,299,108		$	13,661,243
South Africa		2,172,528			2,191,584
Australia		13,068,305			1,434,128
Europe		3,648,133			941,963
Brazil		135,000			145,555
	$	34,323,074		$	18,374,473

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details